Comparative Pharmacology
Head-to-head clinical analysis: DESMOPRESSIN ACETATE versus NOCTIVA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DESMOPRESSIN ACETATE versus NOCTIVA.
DESMOPRESSIN ACETATE vs NOCTIVA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Desmopressin acetate is a synthetic analog of antidiuretic hormone (ADH) that binds to V2 receptors in the renal collecting ducts, increasing water reabsorption and reducing urine output. It also stimulates release of von Willebrand factor and factor VIII from endothelial cells via V2 receptor activation.
Desmopressin is a synthetic analog of vasopressin (antidiuretic hormone) that binds to V2 receptors in the renal collecting ducts, increasing water reabsorption and reducing urine volume.
IV/SC: 0.3-0.4 mcg/kg IV/SC once; may repeat once after 24 hours. Intranasal: 100-400 mcg (0.1-0.4 mL) once; may repeat once after 24 hours. Oral: 300-600 mcg three times daily.
Desmopressin acetate: 1-2 sprays (10-20 mcg) intranasally once daily at bedtime; or 0.1-0.2 mg orally once daily at bedtime.
None Documented
None Documented
Terminal half-life 2-4 hours; prolonged in renal impairment (up to 9 hours)
Terminal elimination half-life is 2-4 hours (mean 3.2 hours) in adults with normal renal function; prolonged to 6-9 hours in moderate renal impairment (CrCl 30-50 mL/min).
Renal (60-70% unchanged), minimal biliary/fecal (<10%)
Renal excretion of unchanged drug accounts for approximately 70% of the dose; fecal elimination constitutes about 20%, with the remainder as metabolites.
Category A/B
Category C
Vasopressin Analog
Vasopressin Analog